Neutrogena contributes to 5% gain in J&J worldwide consumer sales in second quarter.
This article was originally published in The Rose Sheet
Executive Summary
NEUTROGENA CONTRIBUTES TO 5% SALES GAIN IN J&J CONSUMER SALES during the second quarter, Johnson & Johnson reported July 16. Sales for the consumer group reached $1.54 bil., led by the Neutrogena adult skin and hair care products, the recently launched Pepcid AC heartburn remedy and Tylenol analgesics, according to the company. In April, J&J's Neutrogena group introduced a line of "Renova compatible" skin care products with a print ad campaign running in professional publications ("The Rose Sheet" Jan. 22, p. 8)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.